[Non tuberculous mycobacteria pulmonary disease: what's new?].
The incidence of NTM (non tuberculous mycobacteria) pulmonary disease is increasing. The diagnosis must be established in the presence of clinical, radiological and microbiological findings. Groups at risk to contract pulmonary disease due to NTM are patients with underlying structural lung disease. Treatment of NTM is long and requires multiple drugs combinations. Relapses and re-infection are not rare. Our understanding in many matters of NTM pulmonary disease is incomplete. Further research is necessary in order to understand the host's defense mechanisms against NTM, and the factors that influence the evolution to lung disease.
Mazza-Stalder
Jesica
J
Service de pneumologie, Institut de microbiologie CHUV, 1011 Lausanne. Jesica.Mazza-Stalder@chuv.ch
Jaton-Ogay
Katia
K
Nicod
Laurent
L
D000995:Antitubercular Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D015994:Incidence; D018942:Macrolides / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D009165:Mycobacterium Infections, Nontuberculous / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D009170:Nontuberculous Mycobacteria / Q000145:classification / Q000472:pathogenicity; D012008:Recurrence; D012307:Risk Factors; D013183:Sputum / Q000382:microbiology; D013557:Switzerland / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy
D000995:Antitubercular Agents; D018942:Macrolides